Literature DB >> 31630223

Alternative dosing regimens for atezolizumab: right dose, wrong frequency.

Daniel A Goldstein1,2,3, Mark J Ratain4.   

Abstract

The population pharmacokinetics of atezolizumab demonstrate that the trough concentrations are well above the putative target of 6 µg/ml. Thus, alternative dosing schedules are indeed of interest, focusing on reducing the frequency to allow greater patient convenience and reduced costs.

Entities:  

Keywords:  Atezolizumab; Pharmacoeconomics; Pharmacokinetics; Schedule

Year:  2019        PMID： 31630223     DOI： 10.1007/s00280-019-03971-7

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  6 in total

Review 1.  Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology.

Authors:  Etienne Chatelut; Félicien Le Louedec; Gérard Milano
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

2.  Model-based simulation to support the extended dosing regimens of atezolizumab.

Authors:  Chen-Hsi Chou; Li-Feng Hsu
Journal:  Eur J Clin Pharmacol       Date:  2020-08-17       Impact factor: 2.953

Review 3.  Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors.

Authors:  Cody J Peer; Daniel A Goldstein; Jennifer C Goodell; Ryan Nguyen; William D Figg; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2020-06-11       Impact factor: 3.716

Review 4.  Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?

Authors:  Kartik Sehgal; Daniel B Costa; Deepa Rangachari
Journal:  Front Oncol       Date:  2020-06-23       Impact factor: 6.244

Review 5.  Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?

Authors:  Christophe Maritaz; Sophie Broutin; Nathalie Chaput; Aurélien Marabelle; Angelo Paci
Journal:  J Hematol Oncol       Date:  2022-01-15       Impact factor: 17.388

Review 6.  Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course.

Authors:  Mengjie Jiang; Yujie Hu; Gang Lin; Chao Chen
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.